02/21/18 Pharmaceutical Startup, Bridge Therapeutics, Names David H. Bergstrom, Ph.D. as New Chief Operating Officer
The innovative late development-stage pharmaceutical startup, Bridge Therapeutics, has named David H. Bergstrom, Ph.D. as its new Chief Operating Officer effective immediately.
February 21, 2018
Dr. Bergstrom has more than 30 years of new product development and commercialization experience in the pharmaceutical industry. He has overseen and been intimately involved in moving new products from the research phase to eventual successful commercial production. He has also launched products across numerous therapeutic areas and dosage form delivery technologies.
Dr. Bergstrom earned his Ph.D., M.S. and B.S. degrees in Pharmaceutics, Pharmaceutical Chemistry and Pharmacy from the University of Utah, The University of Michigan and Ferris State University, respectively.